Cutaneous malignant lymphoma is a type of skin cancer. Three subtypes of this cancer have a benign clinical behaviour and respond well to treatment. Thus, they were recently reclassified as ‘cutaneous lymphoproliferative disorder’ (LPD). These new names are important as they reflect that these cancers are not malignant. The changes also prompted experts to update the guidance for their treatment. This study presents the new guidelines for LPDs. The study group included 30 centres from Europe and North and South America. They also collaborated with international lymphoma societies. The panel carried out surveys, a literature review and consensus meetings. The guidelines recommend several important changes. Thorough clinical examination is usually the only procedure required. Yet when needed, many treatment options are available. These include surgery, radiotherapy and corticosteroids. Watchful waiting is also suggested, with only symptomatic lesions treated. Follow-up is only required for 2 years, with checkups every 6 months. These recommendations will improve management and treatment in patients with cutaneous LPDs.
European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders
Quaglino, Pietro;
2025-01-01
Abstract
Cutaneous malignant lymphoma is a type of skin cancer. Three subtypes of this cancer have a benign clinical behaviour and respond well to treatment. Thus, they were recently reclassified as ‘cutaneous lymphoproliferative disorder’ (LPD). These new names are important as they reflect that these cancers are not malignant. The changes also prompted experts to update the guidance for their treatment. This study presents the new guidelines for LPDs. The study group included 30 centres from Europe and North and South America. They also collaborated with international lymphoma societies. The panel carried out surveys, a literature review and consensus meetings. The guidelines recommend several important changes. Thorough clinical examination is usually the only procedure required. Yet when needed, many treatment options are available. These include surgery, radiotherapy and corticosteroids. Watchful waiting is also suggested, with only symptomatic lesions treated. Follow-up is only required for 2 years, with checkups every 6 months. These recommendations will improve management and treatment in patients with cutaneous LPDs.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
